|
|
 |
O INSTITUTU ZA ONKOLOGIJU VOJVODINE :: ISTRAŽIVANJA |
 |
| |
Novi
naučni projekti:
 DECENA
- Detekcija cervikalne neoplazije (Vođa projekta: Mr sc
med. dr Jelka Rajović)
Rana
detekcija karcinoma debelog creva u različitim etničkim
grupama Vojvodine (Vođa projekta: Prof. dr sc med. Branimir
Gudurić)
Nova
klinička istraživanja (AKTIVNA FAZA):
Prostate
Cancer: A randomized open-label (ZOMETA® + hormonal
ablation vs. hormonal ablation alone) multicenter prospective
clinical study to show the efficacy of intravenous ZOMETA®
(zoledronic acid) 4 mg for prevention of bone metastases
in hormone-naive high risk patients with locally advanced
prostate cancer, Protocol No. CECOG / prostate 1.2.001.
(Sponzor: CECOG; Glavni istraživač: Prim. dr Dragutin
Donat)
Breast
Cancer: A pharmacokinetic interaction and safety and
efficacy phase II, open label study with a safety lead-in
evaluating docetaxel plus tesmilifene (YMB1002) in patients
with metastatic breast cancer suitable for treatment with
docetaxel, Protocol No. YMB1002-203. (Sponzor: YM Biosciences,
Inc.; Glavni istraživač: Prof. dr sc med. Ljubomir Muzikravić)
Breast
Cancer: A randomized study of docetaxl monotherapy
or DOXIL/CAELYX and docetaxel for the treatment of advanced
breast cancer, Protocol No. DOXIL-BCA-3001. (Sponzor:
Johnson&Johnson; Glavni istraživač: Prof dr Ljubomir
Muzikravić)
Breast Cancer: A multicenter phase 3, randomized comparison
of the safety and efficacy of weekly tocosol paclitaxel
vs. weekly paclitaxel injection in the treatment of metastatic
breast cancer. Protocol No. SON-8184-1075. (Sponzor: Sonus
Pharmaceuticals; Glavni istraživač: Prof. dr sc med. Dušan
Jovanović)
Colorectal
Cancer: A multicenter open label parallel group randomized
phase III clinical trial to evaluate the safety and efficacy
of CoFactor and 5-FU versus leucovorin and 5-F in subjects
with metastatic colorectal carcinoma. Protocol No. 03-CaFactor
(Sponzor: ADVENTRX Pharmaceuticals Inc.; Glavni istraživač:
Prof. dr sc med. Dušan Jovanović)
Colorectal
Cancer: A randomized, double-blind, phase III study
to compare the efficacy and safety of AZD2171 when added
to 5-fluorouracl, leucovorin and oxaliplatin (FOLFOX)
or capecitabine and oxaliplatin (XELOX) with the efficacy
and safety of placebo when added to FOLFOX or XELOX in
patients with previous untreated metastatic colorectal
cancer. Protocol No.: D8480C00051(Sponzor: AstraZeneca;
Glavni istraživač: Prof. dr sc med. Dušan Jovanović)
Pain
Control: A randomized withdrawal, active-a and placebo-controlled,
double-blind multi-centre phase III trial assessing safety
and efficacy of oral CG5503 PR in subjects with moderate
to severe chronic tumor-related pain. Protocol No. KF5503/15.
(Sponzor: Grunenthal GmbH; Glavni istraživač: Mr sc med.
dr Eržebet Patarica-Huber)
Pain
Control: A multicentre, multinational, open-label
trial (including double-blind, placebo/controlled cross-over
extension part) to evaluate the time to significant pain
relief with fentanyl TAIFUN® in the treatment of breakthrough
pain in patients with cancer on maintenance opoid therapy
for persistent pain. Protocol No. CL 700 002 AME3 (Sponzor:
LAB Pharma Ltd; Glavni istraživač: dr Svetlana Salma)
Nova
klinička istraživanja (FOLLOW-UP FAZA):
Randomized
double-blind trial in postmenopausal women with primary
breast cancer who have received adjuvant tamoxifen for
2-3 years, comparing subsequent adjuvant exemestane treatment
with further tamoxifen. Protocol No. 96-OEXE-031 (Sponzor:
Pfizer HCP Corporation; Glavni istraživač Prim. dr D.
Donat)
A
phase III study of DPPE (Tesmilifene) combined with Epirubicin
and Cyclophosphamide versus Epirubicin and Cyclophosphamide
alone as first-line treatment in metastatic/recurrent
breast cancer. Protocol No. YMB 1002-02. (Sponzor: YM
BIOSCIENCES INC.; Glavni istraživač: Prim. dr Dragutin
Donat)
Završena
klinička istraživanja:
Breast
Cancer: A pharmacoknetic
interaction phase I, open label, cross over multicenter
study evaluating the plasma pharmacokinetics of doxorubicn
alone and in combination with tesmilifene in patients
with advanced metastatic breast cancer or other advanced
cancer suitable for treatment with Taxotere. Protocol
No. YMB1002-201. (Sponzor: YM Biosciences, Inc.; Glavni
istraživač: Prof. dr sc med. Ljubomir Muzikravić)
Breast
Cancer: A phase 3 randomized, placebo-controlled,
double-blind study of oral CCI-779 administered in combination
with letrozole vs. Letrozole alone as first-line hormonal
therapy in postmenopausal women with locally advanced
or metastatic breast cancer. Protocol No. 3066A1-303-WW
(Sponzor: Wyeth Research; Glavni istraživač: Dr Jasna
Pešić)
Renal
Cancer: A phase 3, three-arm, randomized, open-label
study of interferon alfa alone, CCI-
779 alone and the combination of interferon alfa and CCI-779
in first-line poor-
prognosis subjects with advanced renal cell carcinoma.
Protocol No. 3066K1-304-WW (Sponzor: Wyeth Pharmaceuticals,
BV; Glavni istraživač: Prim. dr Dragutin Donat)
Urothelial
Tract Cancer: Prospective, randomized phase III trial
of IV vinflunine plus best supportive care as second line
therapy versus best supportive care after a platinum-containing
regimen in patients with advanced cell carcinoma of urothelial
tract, Protocol l00070 in 302 P1 (Sponzor: Pierre Fabre;
Glavni istraživač: Prim. dr Dragutin Donat)
Colorectal
Cancer: A multi-phase II clinical trial to evaluate
the safety and efficacy of weekly treatment with CoFactor™
and 5-fluorouracil in patients with metastatic colorectal
carcinoma, Protocol 02- CoFactor™ (Sponzor: ADVENTRX Pharmaceuticals
Inc.; Glavni istraživač: Prof. dr sc med. Ljubomir Muzikravić)
Pain
Control: A randomized, active control, double-blind,
double-dummy, multi-national, multi-centre study to assess
the efficacy, tolerability and safety of the granisetron
transdermal delivery system (GTDS) in chemotherapy-induced
nausea and vomiting (CINV) associated with the administration
of moderately or highly emetogenic multi-day chemotherapy,
Protocol 392MD/15/C (Sponzor: Strakan Pharmaceuticals
Ltd.; Glavni istraživač: Prim. dr Dragutin Donat)
Završeni
naučni projekti:
Prevencija
ROS oštećenja tokom hemioterapije i radiološke terapije
malignih tumora
Evaluacija
novih primena tehnologije u dijagnostici i terapiji malignih
tumora
Helicobacter
pylori infekcija i maligni tumori želuca
Hemostazni
sistemi i maligni tumori
99NM-Tc-MIBI
scintigrafija i MRI ispitivanje kod tiroidnih malignih
tumora u poređenju sa standardnim vizuelnim metodama
MRI
vizuelizacija u evaluaciji demijelizacionih lezija
Smanjenje
mortaliteta maligniteta grlića materice korišćenjem populacionog
ginekološkog skrininga
Metod
merenja kvaliteta života pacijenata sa inoperabilnim karcinomom
grlića materice posle radiološke terapije
Kvalitet
života pacijenata sa malignim limfomom
Preoperativna
zračenje i adjuvantna hemioterapija kod lokalno uznapredovalog
rektalnog karcinoma; kooperacija sa Skandinavskom grupom
(Karolinska bolnical, Stokholm, Univerzitetska bolnica
Upsala, Švedska)
Antitumorska
terapijara za zaštitu i molekularnu dijagnostiku malignih
alteracija (Vođa projekta: Prof. dr sc med. Zoran Kovacević)
Ocena
mamoscintigrafije i radionuklidne detekcije sentinelnih
žlezda u preoperativnoj dijagnostici i terapiji malignih
tumora dojke (Vođa projekta: Prim. dr Milica Malesević)
Molekularni
mehanizam regulacije apopotoze (smrt ćelija) kod normalnih
i malignih ćelija (Vođa projekta: Prof. dr sc med. Bogdan
Đuričić)
Biološko
ispitivanje hemijski deratinisanog fulerena C-60 (Vođa
projekta: Doc. dr sc med. Aleksandar Đorđević)
Reaktivne
promene žlezdanog epitela u proceni razvoja intenstinalnih
upalnih oboljenja sa atrofijom mukozne membrane. Matematički
model regeneracije (Vođa projekta: Prof. dr sc med. Tamara
Vukavić)
Multimodalna
terapija lokalno uznapredovalog i recidivnog rektalnog
karcinoma i izrada dijagnostičko-prognostičkog modela
(Vođa projekta: Prof. dr sc med. Milan Breberina)
Hirurgija
tumora dojke vođena radioizotopima (Vođa projekta: Prof.
dr sc med. Branimir Gudurić)
Razvoj
telemedicine na Institutu za onkologiju Vojvodine
Laboratorijska
istraživanja:
Biološke
aktivnosti derivata fulerena C60 - in vitro i in vivo
modeli
MRI
i UV-VIS spektroskopija malignih telesnih fluida
Skrining
antitumorskih lekova (cis-platinum derivati, daunorubicin
derivati, tiazofurin derivati)
Primarne
humane kulture ćelija - karakterizacija i identifikacija
Genetske
abnormalnosti kod pacijenata sa limfomima
MDR
studije kod primarnih humanih karcinoma |
|
|
